Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib Intensification Plus Nivolumab in mRCC (AxIn)
NCT05817903Phase 2Recruiting
- Sponsor
- Consorzio Oncotech
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of axitinib in metastatic renal cell carcinoma (mRCC), sponsored by Consorzio Oncotech. Started Apr 2023; status: recruiting.
02
Drugs
axitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT05817903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05817903.